drugset

drugset / Trial / NCT05026632

NPI-002 Intravitreal Implant for the Delay of Cataract Progression

NCT05026632 ↗

Phase 1/2 Active not recruiting 30 enrolled Nacuity Pharmaceuticals, Inc.

RandomizedParallel-groupDouble-blindPrevention

Summary

This study will examine the safety and efficacy NPI-002 intravitreal implants post vitrectomy.

Timeline

Start: 2022-01-27
Primary completion: 2026-09
Completion: 2026-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NPI-002	Unknown	—	Intravitreal

Indications